LivaNova PLC (LIVN) Stock Price & Analysis
LivaNova PLC (LIVN) closed at USD 81.27 on Thursday, October 22, 2026, up 3.61% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 78.44; the Oct 22, 2026 session ranged USD 78.35–81.42 on volume of 522,976 shares. Market capitalization is $4.46B, with a 52-week range of USD 48.82–85.76 (NMS). Source: Nexqual, retrieved October 23, 2026 at 12:06 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LIVN.md
Key facts (LIVN)
- Last four reported quarters (through Jun 30, 2026): revenue $1.47B, net income $189M (12.8% margin), free cash flow $148M (SEC filings).
- Valuation: P/E 23.7x (avg 100.0x at the last 2 fiscal year-ends), EV/EBITDA 19.3x, net cash $227M.
- Earnings quality: non-operating income -$39.4M vs operating income $188M over the last four quarters; P/E excluding non-operating income ≈19.6x (estimate: non-operating income taxed at the company's 0% effective rate).
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $1.0M; 6 not under a Rule 10b5-1 plan ($1.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 90.55 (range 75–105).
- Total return with dividends: 1Y +49.3% vs S&P 500 +14.9%; 5Y +0.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 1.06, revenue estimate $381M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LIVN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B | $1.47B |
| Gross profit | $706M | $707M | $756M | $853M | $940M | — |
| Operating income | -$784K | -$76.8M | -$68.5M | $129M | $199M | $188M |
| Net income | -$136M | -$86.2M | $17.5M | $63.2M | -$242M | $189M |
| EPS (diluted) | -$2.68 | -$1.61 | $0.32 | $1.16 | -$4.45 | — |
| Free cash flow | $77.1M | $43.4M | $39.9M | $136M | $173M | $148M |
| Gross margin | 68.2% | 69.2% | 65.5% | 68.1% | 67.7% | — |
| Operating margin | -0.1% | -7.5% | -5.9% | 10.3% | 14.4% | 12.7% |
| Net margin | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% | 12.8% |
| Revenue growth | +10.8% | -1.3% | +12.9% | +8.7% | +10.7% | — |
| Cash + short-term investments | $208M | $214M | $267M | $429M | $636M | — |
| Total debt | $237M | $539M | $586M | $627M | $376M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (LIVN)
P/E 23.7x · P/E ex non-operating (est.) ≈19.6x · P/S 3.0x · EV/EBITDA 19.3x · EV/Sales 2.9x · P/FCF 30.1x · P/B 3.4x · FCF yield 3.32% · Earnings yield 4.22% · Net cash $227M · EV $4.24B
P/E at fiscal year-ends: Dec 2024 40.0x, Dec 2023 159.9x.
Insider sales (SEC Form 4, open-market, last ~7 months) (LIVN)
0 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Bianchi Francesco | Director | 3,500 | $273K | 44.1% | No | Too little history (no open-market trades in 2023) |
| 2026-09-04 | Story Brooke | Director | 2,300 | $187K | 23.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-31 | Bianchi Francesco | Director | 1,650 | $132K | 17.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Tezel Ahmet | Chief Innovation Officer | 2,675 | $208K | 30.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-15 | Bianchi Francesco | Director | 1,200 | $96K | 11.1% | No | Too little history (no open-market trades in 2023) |
| 2026-05-26 | Bianchi Francesco | Director | 1,800 | $136K | 19.9% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LIVN)
Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 90.55 (low 75, high 105).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Overweight | $105 |
| 2026-09-02 | Piper Sandler | Target raised | Overweight | $87 → $90 |
| 2026-08-05 | Needham | Target raised | Buy | $81 → $93 |
| 2026-07-15 | Mizuho | Target raised | Outperform | $90 → $95 |
| 2026-07-01 | Freedom Capital Markets | Initiated | Hold | $81 |
Total return (dividends reinvested) (LIVN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +49.3% | +0.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +49.5% | +0.1% |
| Volatility (annualized) | 35.7% | 40.5% |
| Max drawdown | -18.9% (Feb 2026→May 2026) | -63.2% (Nov 2021→Apr 2025) |
LIVN revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Cardiopulmonary | $221.6M | 56.7% | +11.2% |
| Neuromodulation | $166.9M | 42.7% | +10.1% |
| Total revenue | $390.6M | 100% | — |
LIVN revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $199.3M | 51.0% | +5.8% |
| Rest of World | $109.4M | 28.0% | +12.5% |
| Europe | $81.8M | 20.9% | +22.5% |
| Total revenue | $390.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
LIVN company outlook (results filed Aug 5, 2026)
- “Lowered full-year 2026 adjusted free cash flow range to $140 million to $160 million • Entered into a long-term agreement with Thermo Fisher Scientific that is anticipated to increase availability of a critical oxygenator component.”
Quoted word-for-word from the SEC 8-K results press release.
LIVN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.06 | $1.08 | -2.2% | $381.1M | 10 |
| Next quarter (ends Dec 2026) | $1.06 | $1.09 | -3.5% | $390.2M | 10 |
| Current fiscal year (ends Dec 2026) | $4.36 | $4.25 | +2.6% | $1.52B | 10 |
| Next fiscal year (ends Dec 2027) | $4.68 | $4.62 | +1.4% | $1.63B | 10 |
LIVN options: expected move
Options price a move of about ±10.1% (±$8.23) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±12.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 44.2% | ±10.1% |
| Dec 18, 2026 | 56 | 40.4% | ±12.9% |
| Jan 15, 2027 | 84 | 37.3% | ±14.4% |
| Apr 16, 2027 | 175 | 37.4% | ±20.5% |
30-day implied volatility 45.8% vs 25.4% realized over the last 30 trading days. Put/call ratio (volume) 0.15. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:06 UTC)
| Price | USD 81.27 |
|---|---|
| Change | ▲ 3.61% (up) |
| Previous Close | USD 78.44 |
| Open | USD 78.7 |
| Day Range | USD 78.35 – 81.42 |
| 52-Week Range | USD 48.82 – 85.76 |
| Volume | 522,976 shares |
| Market Cap | $4.46B |
| Exchange | NMS |
Technical Analysis (LIVN)
Nexqual's technical model rates LIVN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 12:06 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.46 (neutral) |
| vs SMA50 | Above (USD 78.53) |
| MACD | 0.34 (positive) |
Analyst Ratings (LIVN)
Wall Street analysts rate LIVN "Buy" based on 11 analysts, with a mean price target of USD 90.55 (range USD 75–105), per Nexqual as of October 23, 2026 at 12:06 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 90.55 |
| High Target | USD 105 |
| Low Target | USD 75 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (LIVN)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 1.06 |
| Revenue Estimate | $381.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.26 vs est 1.09 ▲ beat |
| 2026-03-31 | USD 0.98 vs est 0.9 ▲ beat |
| 2025-12-31 | USD 0.86 vs est 0.81 ▲ beat |
| 2025-09-30 | USD 1.11 vs est 0.92 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:06 UTC.
Financials & Fundamentals (LIVN)
| Total Revenue | $1.47B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.80% |
| Gross Margin | +67.74% |
| Operating Margin | +13.54% |
| Profit Margin | +12.81% |
| ROE | +15.40% |
| Debt / Equity | 0.27 |
| Current Ratio | 1.45 |
| Total Cash | $516.62M |
| Total Debt | $351.95M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $148.31M (10.1% of revenue) |
Source: Nexqual, October 23, 2026 at 12:06 UTC.
Financial Health Score (LIVN)
Nexqual rates LivaNova PLC's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 12:06 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 14% (last 12 months) |
| Balance Sheet | Strong — $517M cash and investments vs $290M debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $148M (last 4 quarters to Jun 2026, SEC), 10% margin |
| Efficiency | Solid — ROE 15%, ROA 5.0% |
Ownership (LIVN)
| Insider Ownership | +0.41% |
|---|---|
| Institutional Ownership | +112.68% |
| Shares Outstanding | 54.93M |
| Float | 54.84M |
| Short % of Float | +12.51% |
Source: Nexqual, October 23, 2026 at 12:06 UTC.
Leadership (LIVN)
LivaNova PLC is led by Vladimir A. Makatsaria, CEO & Director, per Nexqual as of October 23, 2026 at 12:06 UTC.
| CEO & Director | Vladimir A. Makatsaria |
|---|---|
| Chief Financial Officer | Alex Shvartsburg C.M.A. |
| Vice President of Investor Relations | Briana Gotlin |
| Vice President of Corporate Communications | Deanna Wilke |
| Chief Strategy & Corporate Development Officer | Philip Kowalczyk |
Major Backers & Investors (LIVN)
Notable institutional backers of LivaNova PLC include Primecap Management Company, FMR, LLC, Hood River Capital Management LLC, according to Nexqual as of October 23, 2026 at 12:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 7.57% |
| FMR, LLC | 5.71% |
| Hood River Capital Management LLC | 4.66% |
| AQR Capital Management, LLC | 4.28% |
| Invesco | 4.06% |
| Artisan Partners Limited Partnership | 4.04% |
| American Century Companies Inc | 3.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.73% |
| State Street | 3.93% |
| Vanguard Group | 3.45% |
Source: Nexqual, October 23, 2026 at 12:06 UTC.
From LivaNova PLC's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- LivaNova PLC is a market-leading global medical technology company.
- In 2005, the FDA approved the VNS Therapy System for the adjunctive treatment of chronic or recurrent depression for patients 18 years or older who are experiencing a major depressive episode and have not had an adequate response to four or more antidepressant treatments.
- The GDPR also requires LivaNova to implement a number of accountability measures in relation to the processing of sensitive data, including carrying out Data Protection Impact Assessments and appointing a Data Protection Officer.
- Administrative fines may be levied for non-compliance with the GDPR's requirements and can reach the higher of €20 million ($23.5 million as of December 31, 2025) or up to 4% of LivaNova's total worldwide annual net revenue for the preceding financial year.
Partnerships
- Violations can also result in criminal penalties, including criminal fines of up to $50,000 and imprisonment for up to 10 years.
- Finally, LivaNova offers internships and apprenticeships across functions around the globe, in partnership with universities and institutions, which may lead to full-time employment with the Company.
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to LivaNova's Indebtedness
- Any of these factors could harm LivaNova's business, results of operations, cash flows, and financial condition.
- The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect LivaNova's liquidity and operating results.
- The effective interest rate of the 2029 Notes is significantly greater than the stated interest rate, which may result in volatility to the Company's reported interest expense and financial results and could adversely affect the price at which LivaNova's ordinary shares trade.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ITGR | Integer Holdings Corporation | USD 126.56 | ▼ 0.11% |
| IRTC | iRhythm Holdings, Inc. | USD 119.64 | ▲ 5.36% |
| HAE | Haemonetics Corporation | USD 116.16 | ▼ 0.81% |
| NEOG | Neogen Corporation | USD 11.98 | ▲ 1.61% |
| TMDX | TransMedics Group, Inc. | USD 72.06 | ▼ 0.47% |
| UFPT | UFP Technologies, Inc. | USD 297.33 | ▲ 2.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:06 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt